No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for development milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for development, regulatory and sales milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The next potential milestone payment to be earned under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_NextPotentialMilestonePayment
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of shares received from the subsidiary during the period.

+ References

No definition available.

+ Details

Name:	ions_ReceiptOfSharesInSubsidiary
Namespace Prefix:	ions_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of separate performance obligations under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.

+ References

No definition available.

+ Details

Name:	ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_RoyaltyPercentageReceivedOnNetSalesOfDrug
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the sublicense fee paid in common stock.

+ References

No definition available.

+ Details

Name:	ions_SublicenseFeePaidForLicenseOfDrug
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of upfront payments received during the period under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_UpfrontPaymentReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Pfizer (Details) $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Oct. 31, 2019 USD ($) PerformanceObligation	Feb. 28, 2019 USD ($) shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Additional shares of Akcea stock received (in shares) \| shares		2.8
Sublicense fee paid in stock		$ 75,000
Revenue				$ 1,122,599	$ 599,674	$ 514,179
R&D Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue				770,149	$ 344,752	$ 394,165
Pfizer [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue			$ 246,000
Akcea [Member] \| Pfizer [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront payment received	$ 250,000
Maximum amount of payments receivable for development, regulatory and sales milestones			1,300,000	1,300,000
Maximum amount of payments receivable for development milestones			205,000	205,000
Maximum amount of payments receivable for regulatory milestones			250,000	250,000
Maximum amount of payments receivable for commercialization milestones			850,000	$ 850,000
Royalty percentage received on net sales of drug				20.00%
Next prospective milestone			$ 75,000	$ 75,000
Number of separate performance obligations \| PerformanceObligation	3
Transaction price	$ 250,000
Additional shares of Akcea stock received (in shares) \| shares			6.9
Sublicense fee paid in stock			$ 125,000
Revenue			2,200	248,700
Deferred revenue			1,300	$ 1,300
Akcea [Member] \| Pfizer [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage				22.00%
Akcea [Member] \| Pfizer [Member] \| AKCEA-ANGPTL3-L [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Transaction price	245,600
Revenue			$ 245,600
Akcea [Member] \| Pfizer [Member] \| R&D Services for AKCEA-ANGPTL3-L [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Transaction price	2,200
Akcea [Member] \| Pfizer [Member] \| AKCEA-ANGPTL3-L API [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Transaction price	$ 2,200